NICE publishes Medtech Innovation Briefing on ZedScan

Support for NHS use of cancer diagnostic system

ZedScan

The National Institute for Health and Care Excellence (NICE) has developed a Medtech Innovation Briefing (MIB) on Zilico’s cervical cancer diagnostic system, ZedScan.

NICE first developed the MIB documents in 2013 to help boost the uptake of innovative and promising technologies that have the potential to improve patient health and increase NHS productivity.

MIBs provide a description of a medical technology, including its likely place in therapy, the costs of using the technology, and a critical review of the strengths and weaknesses of the relevant published evidence.

The purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.

The NICE MIB has been developed on ZedScan as an adjunct to colposcopy in women with suspected cervical intra-epithelial neoplasia.

The ZedScan system is used alongside colposcopy on women identified with an abnormal smear result.

ZedScan offers clinical benefits by identifying those patients who require treatment at first visit, reducing the number of cervical biopsies performed on each patient by pin-pointing the optimum site for biopsy and reducing follow-up appointments - benefiting the patient and the hospital.

For both the 'see and treat' and 'triage' clinics, the model showed a reduction in overtreatment, adverse events and related treatment costs

These benefits translate into better health economics as identified in an independent report by the School of Health and Related Research.

The MIB states that this economic evaluation is a ‘well-executed document with a clear statement of limitations and assumptions’.

The NICE MIB for ZedScan identifies three key benefits from the report. It states:

  • “For both the 'see and treat' and 'triage' clinics, the model showed a reduction in overtreatment, adverse events and related treatment costs”
  • “Lower biopsy rates were associated with the ZedScan, with 1–1.02 biopsies per woman having colposcopy with the ZedScan compared with 1.72 with standard care, and this reduced related costs”
  • “A cost saving was also illustrated from the reduction in follow-up colposcopy appointments over the timeframe of the model.”

The MIB also states that ‘NICE is not aware of any other CE-Marked devices that have a similar function to the ZedScan’.

The NICE MIB follows the publication of a peer-reviewed multi-centre study in BJOG: An International Journal of Obstetrics & Gynaecology, a health economics evaluation, and a real-clinic case study on over 500 patients. .

Click here to read the document in full.

Companies